

## Amendments

### Claims

Claims 24-256 are currently pending in light of the amendments above. Claims 1-23 have been canceled without prejudice, and Applicants reserve the right to pursue the subject matter of these claims in this or continuing applications.

New claims 24-256 have been added to more particularly point out and distinctly claim the subject matter Applicants regard as the invention. Support for the newly added claims is found throughout the specification as filed, and no new matter had been introduced.

More particularly, support for new claims can be found in the specification as follows:

Figures 1 and 2 (full length polypeptide) and page 20, lines 21-25 and page 58, line 5 (lack of an N-terminal methionine); page 7, lines 12-23 (mature form and soluble extracellular domain); page 37, lines 1-25 (epitopes); pages 78-90 (N-terminal and C-terminal deletions); pages 54, line 8 to page 55, line 22 (heterologous polypeptides including Fc domains); page 146, line 19 to page 149, line 7 (pharmaceutical compositions); page 8, lines 1-7 and page 101, lines 7-16 (90% and 95% identity); and page 8, lines 19-24 and pages 109-155 (antibodies).

### Specification

The specification has been amended to conform the references to the figures in the specification to the figure designations in the formal drawings concurrently submitted herewith by Applicants.

### Drawings

Applicants submit concurrently twenty-three (23) sheets of formal drawings containing Figures 1, 2A-B, 3A-P, and 4-7 for entry in the instant application.


The formal drawings are completely supported by the informal drawings as originally filed and no new matter has been introduced. The formal drawings correct minor typographical and/or editorial errors in the sheets of Figure 3 as originally filed. None of the amino acid sequences have been amended. More specifically, the originally filed informal drawings were photocopies of an original figure which had been hole-punched. The hole-punching inadvertently obscured some of the numbering of the amino acids along the left margin of the first five sheets of Figure 3. The corrected amino acid number designations are indicated in red ink on the attached copy of the original informal drawings of Figure 3, in accordance with 37 C.F.R. § 1.121(a)(3)(ii). The correct numbering for the formal drawings of Figure 3 (Figures 3A-P) would be completely obvious to one skilled in the art upon examining the original informal drawings as a whole, by simply counting the amino acids of the sequence. Thus, the correction of the obscured numbers introduces no new matter.

**CONCLUSION**

Applicants respectfully request that the amendments and remarks above be entered and made of record in the file history of the instant application. Should any additional fees be deemed necessary, please charge such fees to Deposit Account No. 08-3425.

Respectfully submitted,

Date: October 25, 2000

  
Jonathan L. Klein (Reg. No. 41,119)  
Attorney/Agent for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 251-6015 (phone)

JKE/MS/rc